Scientific Publications by FDA Staff
Antiviral Res 2013 May;98(2):325-31
Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication.
Debing Y, Kaplan GG, Neyts J, Jochmans D
Three different antiviral assays were developed for the in vitro screening of inhibitors of the hepatitis A virus (HAV) of which (i) a cytopathic effect reduction assay suitable for medium-to-high-throughput screening and (ii) two virus yield reduction assays (based on quantification of viral RNA) for genotypes IB and IIIA. The assays were validated for antiviral studies with interferon-alpha (IFNalpha) and amantadine HCl, two known inhibitors of HAV replication. IFNalpha effectively inhibited HAV replication, whereas the activity of amantadine HCl appeared to be strain-dependent. Employing these assays, we assessed the effect of the known enterovirus inhibitors pleconaril, rupintrivir and enviroxime on HAV replication. Pleconaril exhibited some very moderate activity, the effect of rupintrivir proved to be strain-dependent. Enviroxime did not inhibit HAV replication, suggesting that phosphatidylinositol-4-kinase IIIbeta is not crucial in the HAV life cycle.
|Category: Journal Article|
|PubMed ID: #23528258||DOI: 10.1016/j.antiviral.2013.03.016|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2013-07-14|